International Research journal of Management Science and Technology

  ISSN 2250 - 1959 (online) ISSN 2348 - 9367 (Print) New DOI : 10.32804/IRJMST

Impact Factor* - 6.2311


**Need Help in Content editing, Data Analysis.

Research Gateway

Adv For Editing Content

   No of Download : 132    Submit Your Rating     Cite This   Download        Certificate

AN OVERVIEW ON FLOATING DRUG DELIVERY SYSTEM

    1 Author(s):  AVINASH JIDDEWAR

Vol -  5, Issue- 6 ,         Page(s) : 126 - 137  (2014 ) DOI : https://doi.org/10.32804/IRJMST

Abstract

The purpose this review on floating drug delivery systems (FDDS) was to compile the recent literature with special focus on the principal mechanism of floatation to achieve the physiological and formulation variables affecting gastric retention, approaches to design Effervescent and Noneffervescent floating systems, and their classification and formulation aspects. It is known that differences in gastric physiology (such as, gastric pH, motility) exhibit both intra- as well as inter-subject variability demonstrating significant impact on gastric retention time and drug delivery behavior The floating or hydrodynamically controlled drug delivery systems are useful in such application. From the formulation and technological point of view, the floating drug delivery system is comparatively easy and logical approaches are discussed.

1. Viswanatha Reddy M, Jayashankar Reddy V, Ramesh Y, Venkateswarlu I. Research Journal of Pharmaceutical, Biological and Chemical Sciences, 2(3), 2011, 722. 
2. El-Kamel, A.H., Sokar, M.S., Al Gamal, S.S., Naggar. Preparation and evaluation of ketoprofen floating oral delivery system. Int J Pharm. 2001; 220, 13-21.
3. Robinson J.R, Lee V.H.L. Controlled drug delivery: fundamentals and applications. 2nd ed. Marcel Dekker Inc; NY 1987.
4. 3.Hirtz J. The git absorption of drugs in man: a review of current concepts and methods of investigation. Br J Clin Pharmacol. 1985;19:77-83.
5. Sangekar S., Evaluation of effect of food and specific gravity of the tablets on gastric retention time. Int.J.Pharm,35(3); 34-53, (1987)
6. Chawla G, Gupta P, Koradia V and Bansal AK., Gastroretention: A Means to Address Regional Variability in intestinal drug Absorption. Pharmaceutical technology, 27(2); 50-68, (2003)
7. Sheth PR and Tossounian J., The Hydrodynamically Balanced System (Hbs™): A Novel Drug Delivery System for Oral Use. Informa healthcare, 10(2); 313- 339, (1984) 
8. S. Garg, S. Sharma. Gastroretentive drug delivery system. Business Briefing: Pharmatech. 2003;160-166.
9. Rubinstein, D. R. Friend. Specific delivery to the gastrointestinal tract, in: A. J. Domb (Ed.), polymeric sitespecific Pharmacotherapy. Wiley, Chichester. 1994.282-283.S
10. Ichikawa M, Watanabe S, Miyake Y. A new multiple unit oral floating dosage system. I: Prepration and in vitro evaluation of floating and sustained-release kinetics. J Pharm Sci. 1991; 8:1062-1066.
11. Gu T.H. Pharmacokinetics and pharmacodynamics of diltiazem floating tablets. Chung Kao Yao Li Hsuesh Pao.1992; 13:527-531.
12. Rouge N., Cole E.T., Doelker E., Buri P. Buoyancy and drug release patterns of floating mini tablets containing piretanide and atenolol as model drugs. Pharm. Dev. Technol. 1998; 3:73-84.
13. Cheuh H.R., Zia H., Rhodes C.T. Optimization of Sotalol floating and bioadhesive extended release tablet formulation. Drug Dev. Ind. Pharm. 1995; 21:1725-1747. 
14. Nur A.O., Zhang J.S.. Captopril floating and/or bioadhesive tablets: design and release kinetics.Drug Dev Ind Pharm. 2000; 26:965-969.
15. Babu VBM, Khar RK. In vitro and In vivo studies of sustained release floating dosage forms containing salbutamol sulphate. Pharmazie. 1990; 45: 268-270.
16. Hetal N Kikani, A Thesis on, Floating Drug Delivery System, The North Gujarat University, Patan, 2000-2001; 11-12.
17. Babu, V.B.M., Khar, R.K. (1990). In vitro and In vivo studies of sustained release floating dosage forms containing salbutamol sulphate. Pharmazie.; 45: 268-270. PMid:2381979
18. Fell J T, Whitehead L, Collet H, Prolonged gastric trtention using floating dosage forms, Pharm Technol. 2000; 24(3):82-90.
19. Moursy NM, Afifi NH, Ghorab DM, El-Saharty Y. Formulation and evaluation of sustained release floating capsules of Nicardipine hydrochloride. Pharmazie. 2003; 58:38-43.
20. Timmermanns J. and Moes A. (1990). How well do floating dosages forms float? Int.J.Pharm.1987; 62(3): 207 – 216.
21. Chen G.L., Hao W.H., In vitro performance of floating sustained release capsules of verapamil. Drug Dev Ind Pharm.1998; 24:1067-1072.
22. Moursy N.M., Afifi N.N., Ghorab D.M., El- Saharty Y.Formulation and evaluation of sustained release floating capsules of Nicardipine hydrochloride. Pharmazie. 2003; 58:38-43.
23. http://www.pharmabiz.com, Basak S, Chronicle Specials, Floatable Gastroretentives: Emerging Potentials, Mar- 2006.
24. Ritschel W A. Targeting in the gastrointestinal tract: new approaches, methods find. Exp. Clin. Pharmacol. 1991; 13:313-336.
25. Talukder R, Fassihi R. Gastroretentive drug delivery system: A Mini Review. Drug Dev Ind Pharm 2004; 30(10):1019-1028.
26. Klausner EA, Lavy E, Stepensky D, Friedman M, Hoffman A. Novel gastroretentive dosage form: evaluation of gastroretentivity and its effect on riboflavin absorption in dogs. Pharm. Res.2002; 19:1516-1523.
27. Fell J., Digenis C.G. Imaging and behavior of solid oral dosage forms in vivo. Int.J.Pharm.1984; 22(1):1-5.
28. Gansbeke, B.V., Timmermans J., Schoutens A and Moes A.J. Intragastric positioning of two concurrently ingested pharmaceutical matrix dosage forms, Nucl Med Biol.1991;18:711-718.
29. Jao, F., Edgren, D E. and Wong, P S. (2000). Gastric retention dosage form havin multiple layers. Int Application WO0038650.July, 2006.
30. Hendee, W. R. In Textbook of Diagnostic Imaging II, 2nd Ed., W B Saunders, Philadelphia, 1999; 1:1-6.

*Contents are provided by Authors of articles. Please contact us if you having any query.






Bank Details